Risks and Benefits of Continuing Renin-Angiotensin-Aldosterone System Inhibitors in Critically-Ill Patients

被引：0

作者：

Chou, Ruey-Hsing ^{[1
,2
,3
,4
]}

Yang, Shang-Feng ^{[4
,5
]}

Huang, Po-Hsun ^{[2
,4
,6
]}

机构：

[1] Natl Yang Ming Chiao Tung Univ, Dept Crit Care Med, Hsinchu, Taiwan

[2] Natl Yang Ming Chiao Tung Univ, Taipei Vet Gen Hosp, Dept Med, Div Cardiol, Hsinchu, Taiwan

[3] Natl Yang Ming Chiao Tung Univ, Cardiovasc Res Ctr, Hsinchu, Taiwan

[4] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Hsinchu, Taiwan

[5] Cheng Hsin Gen Hosp, Dept Med, Div Nephrol, Taipei, Taiwan

[6] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Med, Taipei, Taiwan

来源：

ACTA CARDIOLOGICA SINICA | 2024年 / 40卷 / 02期

关键词：

ACEi; angiotensin-converting enzyme inhibitor; AKI; acute kidney injury; ARB; angiotensin receptor blocker; eGFR; estimated; glomerular filtration rate; ICU; intensive care unit;

D O I：

10.6515/ACS.202403_40(2).20231206B

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We read with interest the letter by Ali Coner et al. responding to our previously published article.1 Dr. Coner suggested drug administration in intensive care units (ICU) should be arranged based on hemodynamic status. They requested us to compare patients who continued renin-angiotensin-aldosterone system (RAAS) inhibitors during ICU stay and those who withdrew in terms of clinical outcome. They also suggested we provide the reasons for withdrawing RAAS inhibitors. Because our institution did not have a standardized protocol guiding

引用

页码：260 / 261

页数：2

共 50 条

[41] RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSION
WEIDMANN, P
SIEGENTHALER, W
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1967, 92 (43) : 1953 - +
[42] Gender and the renin-angiotensin-aldosterone system
Komukai, Kimiaki
Mochizuki, Seibu
Yoshimura, Michihiro
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2010, 24 (06) : 687 - 698
[43] Overview of renin-angiotensin-aldosterone system
Mitsuyama, Shokei
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2009, 109 : 17P - 17P
[44] Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney
van den Heuvel, Mieke
Batenburg, Wendy W.
Jainandunsing, Sjaam
Garrelds, Ingrid M.
van Gool, Jeanette M. G.
Feelders, Richard A.
van den Meiracker, Anton H.
Danser, A. H. Jan
JOURNAL OF HYPERTENSION, 2011, 29 (11) : 2147 - 2155
[45] Evaluation of Vasopressin for Septic Shock in Patients on Chronic Renin-Angiotensin-Aldosterone System Inhibitors
Erwin, Beth L.
Denaburg, Michael A.
Barker, Andrew B.
McArdle, Philip J.
Windham, Samuel T.
Morgan, Charity J.
CRITICAL CARE MEDICINE, 2017, 45 (12) : e1226 - e1232
[46] Recommendations for the management of hyperkalemia in patients receiving renin-angiotensin-aldosterone system inhibitors: comment
Ozdede, Murat
Guven, Alper Tuna
INTERNAL AND EMERGENCY MEDICINE, 2024, 19 (03) : 879 - 881
[47] Patients adherence with fixed dose combinations of renin-angiotensin-aldosterone system inhibitors in hypertension
Simonyi, G. A.
Ferenci, T.
Finta, E.
Balogh, S.
Medvegy, M.
EUROPEAN HEART JOURNAL, 2019, 40 : 2780 - 2780
[48] Effect of renin-angiotensin-aldosterone system inhibitors on Covid-19 patients in Korea
Park, Jungchan
Lee, Seung-Hwa
You, Seng Chan
Kim, Jinseob
Yang, Kwangmo
PLOS ONE, 2021, 16 (03):
[49] Is diabetes still a compelling indication for renin-angiotensin-aldosterone system inhibitors?
Fakheri, Joseph
Bangalore, Sripal
Messerli, Franz
CLEVELAND CLINIC JOURNAL OF MEDICINE, 2020, 87 (01) : 9 - 9
[50] In pursuit of balance: renin-angiotensin-aldosterone system inhibitors and hyperkalaemia treatment
Sciatti, Edoardo
D'Elia, Emilia
Balestrieri, Giulio
D'Isa, Salvatore
Iacovoni, Attilio
Senni, Michele
EUROPEAN HEART JOURNAL SUPPLEMENTS, 2023, 25 : C301 - C305

← 1 2 3 4 5 →